Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

About this update from Adaptogenics Health Corp.

[{"type":"text","content":"Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell LymphomaclonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remission\n\n\n\n SEATTLE, April 08, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses diagnostic technologies through its Molecular Diagnostic Services Program (MolDX), has expanded coverage of clonoSEQ\n \n ®\n \n to include single time point testing to monitor for recurrence in patients with a history of mantle cell lymphoma (MCL).\n \n\n This expanded coverage is in addition to the existing Medicare episode payment structure for clonoSEQ, which provides coverage for a bundle of tests to assess response to therapy while a patient is being treated. Under the expanded coverage decision, patients who have completed treatment are now covered to receive clonoSEQ testing every six months for up to five years during treatment-free remission and annual testing thereafter until disease recurrence is detected. MCL is the first clonoSEQ indication to receive this determination and pricing will be consistent with the recently updated Clinical Laboratory Fee Schedule (CLFS) rate of $2,007 per clonoSEQ test.\n \n\n “Securing coverage for clonoSEQ use in the MCL surveillance setting is a significant win for MCL patients. This coverage expansion enables clinicians to more effectively monitor and manage these patients who are at risk of relapse,” said Ben Eckert, senior vice president, Market Access, Adaptive Biotechnologies. “We believe this determination underscores the clinical utility of clonoSEQ testing and establishes a framework for potential expanded coverage of surveillance testing in other Medicare-covered clonoSEQ indications.”\n \n\n MCL is a sub-type of non-Hodgkin lymphoma (NHL) with an annual incidence of approximately 4,000 cases per year in the United States.\n \n 1\n \n MRD is assessed through a series of tests over an MCL patient’s cancer journey and leverages blood to assess response, understand progn...

More updates from Adaptogenics Health Corp.